|1.||Stasch, Johannes-Peter: 4 articles (01/2013 - 01/2002)|
|2.||Mika, Alice: 3 articles (09/2015 - 09/2011)|
|3.||Peters, Harm: 3 articles (09/2015 - 09/2011)|
|4.||Loof, Tanja: 3 articles (09/2015 - 09/2011)|
|5.||Neumayer, Hans-H: 2 articles (09/2015 - 09/2011)|
|6.||Watts, John A: 2 articles (04/2013 - 12/2011)|
|7.||Fulkerson, Mary-Beth K: 2 articles (04/2013 - 12/2011)|
|8.||Gellar, Michael A: 2 articles (04/2013 - 12/2011)|
|9.||Kline, Jeffrey A: 2 articles (04/2013 - 12/2011)|
|10.||Evgenov, Oleg V: 2 articles (01/2013 - 12/2007)|
09/01/2011 - "Rats were randomly assigned to unilateral ureteral obstruction and unilateral ureteral obstruction plus BAY 41-8543 (10 mg/kg body weight daily). "
09/01/2011 - "We analyzed the action of the specific soluble guanylate cyclase stimulator BAY 41-8543 on the renal recovery phase in rats with unilateral ureteral obstruction after obstruction was relieved. "
07/01/2012 - "After 5-day unilateral ureteral obstruction female and male rats were assigned to obstruction relief alone or obstruction relief plus 7-day treatment with the soluble guanylate cyclase stimulator BAY 41-8543. "
09/01/2011 - "Soluble guanylate cyclase stimulation by BAY 41-8543 increases cyclic guanosine monophosphate production and subsequently enhances renal recovery after unilateral ureteral obstruction relief through an array of pathways. "
09/01/2015 - "Soluble guanylate cyclase stimulator BAY 41-8543 and female sex ameliorate uremic aortic remodeling in a rat model of mild uremia."
09/01/2015 - "This study investigates the effects of biological sex and nitric oxide-independent soluble guanylate cyclase (sGC) stimulator BAY 41-8543 on aortic remodeling in experimental mild uremia. "
|3.||Hypertension (High Blood Pressure)
01/01/2002 - "This study investigates the acute effects of BAY 41-8543 on haemodynamics in anaesthetized rats and dogs, its long-term effects in conscious hypertension rat models and its antiplatelet effects. "
01/01/2002 - "In a low NO, high renin rat model of hypertension, BAY 41-8543 prevented the increase in blood pressure evoked by L-NAME and reveals a kidney protective effect. "
12/01/2011 - "Treatment of 5-hr moderate pulmonary embolism with BAY 41-8543 (50 μg/kg) caused a 2.2-fold increase in cardiac output (59 mL/min) with a 46% reduction in right ventricular peak systolic pressure (38 mm Hg), suggesting significant pulmonary vasodilation. "
12/01/2011 - "Five hrs moderate pulmonary embolism increased right ventricular peak systolic pressure (from 28 to 47 mm Hg) and decreased cardiac output (from 48 to 27 mL/min), causing right ventricular peak systolic pressure/cardiac output to increase from 0.6 control with no pulmonary embolism to 1.8 mm Hg/mL/min in 5-hr moderate pulmonary embolism + solvent for BAY 41-8543. "
04/01/2013 - "A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism."
12/01/2011 - "Pulmonary vascular reserve during experimental pulmonary embolism: effects of a soluble guanylate cyclase stimulator, BAY 41-8543."
|5.||Pulmonary Hypertension (Ayerza Syndrome)
12/01/2007 - "We tested whether inhalation of novel dry-powder microparticle formulations containing sGC stimulators (BAY 41-2272, BAY 41-8543) or an sGC activator (BAY 58-2667) would produce selective pulmonary vasodilation in lambs with acute pulmonary hypertension. "
06/30/2012 - "The decreases in pulmonary arterial pressure in response to iv injections of sodium nitroprusside, sodium nitrite, and BAY 41-8543 were not different in rats with monocrotaline-induced pulmonary hypertension and rats with chronic nitrite therapy when compared to responses in animals in which pulmonary arterial pressure was increased with U46619. "
|1.||Guanylate Cyclase (Guanylyl Cyclase)
|2.||Nitric Oxide (Nitrogen Monoxide)
|3.||3- (4- Amino- 5- cyclopropylpyrimidine- 2- yl)- 1- (2- fluorobenzyl)- 1H- pyrazolo(3,4- b)pyridine
|4.||15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
|5.||NG-Nitroarginine Methyl Ester (L-NAME)
|9.||Nitroprusside (Sodium Nitroprusside)
|10.||5'-Guanylic Acid (GMP)